What happened
Eighteen of twenty-one analysts still rate Alnylam as a buy or equivalent. The stock has fallen recently, but Wall Street expects a bigger rebound. Analysts point to a solid drug portfolio, upcoming data readouts, and potential regulatory milestones as reasons for upside. A strong balance sheet adds to the case. While some risk remains, the majority see room for shares to recover if catalysts land as expected.
Why it matters
A high share of buy ratings signals confidence from analysts despite recent weakness. In biotech, prices can swing on a few data events or regulatory decisions, so optimism can matter for investor sentiment. If the expected catalysts hit, the gap between the current price and targets could shrink. However, biotech still carries execution and approval risks, so outcomes can diverge from expectations.
What to watch
Watch for upcoming trial results and any regulatory decisions on key programs. Look for news on new indications or label expansions. Also monitor the company’s cash runway and any changes in cost management. Finally, general biotech market sentiment can influence how investors price potential catalysts.